We use our technology to support all aspects of preclinical drug discovery and biomedical translational research with a particular focus on disease of the nervous system.
NeuroSolutions has been performing first class contract research since 2001 and continues to support the biopharmaceutical industry in developing new treatments for diseases occurring throughout the central and peripheral nervous system.
Browse the breadth and depth of NeuroSolutions publications detailing our experience in rodent and non-human primate tissues.
Prophylactic Tetrodotoxin Treatment of a Rat Model of Oxaliplatin-Induced Peripheral Neuropathy.
In vitro electrophysiological recordings of multiple brain regions from aged pig tailed Macaques.
A rodent in vitro sciatic nerve DRG and dorsal root preparation in naïve and CCI model animals.
An in vivo study of the site of action of SD118/SNL043 in cci rats.
Potentiation of reflex blinks by glyceryl trinitrate in the rat: A novel model for migraine.
Predicting Anxiety Related Behaviour – Using Spatial Learning Test.
Effects of nitric oxide on electrotonically coupled neonatal rat SPN in vitro and in vivo.
Pregnenolone sulphate potentiates NMDA-receptor mediated responses in vitro and in vivo.
Identification of two gating modes of Nav1.8
Behavioural and electrophysiological study on a Rat model of paclitaxel-induced Neuropathy.
Murine Models of Neuropathic Pain.
A novel compound, SEN606 recovers Amyloid β 1-42 induced depression of LTP in vitro.
"Thank you for the absolutely phenomenal work you have done for Redpin. As biotech managers, we frequently push CROs to the max and sometimes take them for granted. After reviewing the work that you have done over the past year, I felt that I needed to let you know what a difference you had made to Redpin’s growth and success. Your work has been of the highest caliber and your dedication unmatched."
Elma Hawkins PhD, MBA, former President and CEO Redpin Therapeutics, Inc.
"I have worked with NeuroSolutions on many projects over many years. The quality of the data is second to none, their scientific expertise and collaborative approach to our technicality demanding projects has been excellent. For example, the work on SEN1576 has led to high-impact joint publications with Senexis and this compound is now being developed by Talisman Therapeutics.."
Dr Mark Treherne - As former Chief Executive of Senexis Limited (Dr Treherne is currently Chief Executive of Life Sciences Organisation at UK Trade & Investment, which helps UK business trade overseas).
Email: info@nsolns.com
Contact Head-office on +44 (0) 8454 500171
One of our partner companies may be better suited to your requirements